Showing 2 of 10 years of data. Sign up free for 5 years of history.
View PlansProcter & Gamble Health (PGHL) reported revenue of ₹9.45B in FY2025 with net income of ₹2.34B. Total assets stood at ₹7.94B and free cash flow was ₹1.60B.
Procter & Gamble Health Income Statement
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Revenue | 11.67B | 9.45B | |
| Cost of Rev. Cost of Revenue | -3.31B | -2.63B | |
| Gross Profit | 8.36B | 6.82B | |
| SGA Sales, General & Admin | -5.15B | -3.53B | |
| Op. Income Operating Income | 2.94B | 3.12B | |
| PBT Profit Before Tax | 2.73B | 3.12B | |
| Net Income | 2.01B | 2.34B | |
| Dil. Shares Diluted Shares | 16.60M | 16.60M | |
| Diluted EPS | 121.07 | 141.22 |
Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.
Understanding the Income Statement
The income statement shows Procter & Gamble Health's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.
Procter & Gamble Health Balance Sheet
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Curr. assets Total current assets | 5.24B | 5.26B | |
| Non-curr. assets Total non-current assets | 2.70B | 2.68B | |
| Total assets | 7.94B | 7.94B | |
| Curr. liabilities Total current liabilities | 2.19B | 2.15B | |
| Non-curr. liab. Total non-current liabilities | 372.10M | 419.30M | |
| Total liabilities | 2.56B | 2.57B | |
| Total equity | 5.38B | 5.37B | |
| Total liab. & eq. Total liabilities & equity | 7.94B | 7.94B |
Figures in ₹ — millions (M), billions (B), trillions (T).
Understanding the Balance Sheet
The balance sheet captures Procter & Gamble Health's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.
Procter & Gamble Health Cash Flow Statement
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 2.73B | 3.12B | |
| Operating CF Cash flow Operating Activities | 2.28B | 1.69B | |
| Capex Investments in PPE | -217.30M | -85.60M | |
| Investing CF Cash flow Investing Activities | -68.70M | 95.90M | |
| Dividend Paid | -4.15B | -2.32B | |
| Financing CF Cash flow Financing Activities | -4.18B | -2.35B | |
| Cash (start) Cash at beginning of period | 4.35B | 2.39B | |
| Cash (end) Cash at end of period | 2.39B | 1.82B | |
| FCF Free Cash Flow | 2.07B | 1.60B |
Figures in ₹ — millions (M), billions (B), trillions (T).
Understanding Cash Flow
The cash flow statement tracks how Procter & Gamble Health's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025
Now find out what Procter & Gamble Health is worth
You've seen the statements. A paid plan turns those numbers into a verdict — fair-value estimates, undervalued-stock screening, and ownership signals.
- Fair value from 5 models — DCF, DDM, P/E, P/B & EPS growth
- Undervalued-stock screener across 500+ companies
- Insider trades, bulk deals & promoter shareholding trends
Related Stocks
Caplin Point (CAPLIPOINT)
Revenue grew 15.5% to ₹2,034 Cr in FY2025.
Jubilant Pharmova (JUBLPHARMA)
Revenue of ₹7,291 Cr in FY2025.
Strides Arcolab (STAR)
Turned profitable with net income of ₹3,598 Cr in FY2025.
Biocon (BIOCON)
Revenue compounded at 18.2% annually over 10 years.
Pfizer (PFIZER)
Revenue of ₹2,454 Cr in FY2025.
Natural Capsule (NATCAPSUQ)
Revenue of ₹170 Cr in FY2025.